Executive Vice President, Chief Scientific Officer · Aligos Therapeutics, Inc. (ALGS)

Julian Symons

A named executive officer of Aligos Therapeutics in every fiscal year CompBrief holds from FY2020 to FY2025. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$1,078,522

Salary $492,758Stock awards $0

FY2024: $834,517

3rd of 3 named executive officers at Aligos Therapeutics by FY2025 total.

3 named officers on file for Aligos Therapeutics, FY2025

Julian Symons’s pay file — $29

  • 6 fiscal years of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Aligos Therapeutics’s whole pay program stands against its peers

  • Aligos Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ALGS→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 29, 2026 (DEF 14A).

Free

Get Julian Symons’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Julian Symons compensation by year

Aligos Therapeutics Summary Compensation Table · all 6 fiscal years held
In US dollars, as Aligos Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020FY2021FY2022FY2023FY2024FY2025
Salary$336,675$435,839$455,451$473,669$487,879$492,758
Bonus$0$0$0$0$0$0
Stock awards$0$0$0$0$0$0
Option awards$2,248,233$0$328,189$100,804$157,050$384,545
Non-equity incentive$210,550$165,549$151,210$215,993$177,588$189,219
Pension and deferred compensation$0$0$0$0$0$0
All other$32,885$17,434$12,000$45,853$12,000$12,000
Total$2,828,343$618,822$946,850$836,319$834,517$1,078,522

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Aligos Therapeutics, Inc. DEF 14A filed April 29, 2026, accession 0001193125-26-191843, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Aligos Therapeutics, Inc. filed document, accession 0001193125-26-191843. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2026.

$2.8M
$619K
$947K
$836K
$835K
$1.1M
FY20
FY21
FY22
FY23
FY24
FY25
SalaryNon-equity incentiveOption awardsAll other

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
Option7,480—$11.74
Option14,334—$8.68
Option17,174—$16.87
Option1,620—$28.25
Option760—$21.00
Option984—$33.50
Option291—$35.25
Option124—$24.00

Per the Outstanding Equity Awards at Fiscal Year-End table in Aligos Therapeutics, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.

Aligos Therapeutics’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Lawrence BlattPresident and Chief Executive Officer$4,057,234
Lesley CalhounExecutive Vice President, Chief Operating Officer and Chief Financial Officer$1,579,689
Julian Symons · this pageExecutive Vice President, Chief Scientific Officer$1,078,522

The full Aligos Therapeutics compensation record

free company brief

This page is one person within Aligos Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Aligos Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Julian Symons's compensation dossier · One-time report. No refunds.